Harborside


Nova Mentis Life Science Corp.

CNSX: NOVA


Canadian symbol: NOVA.CN
US symbol: NMLSF

Currency in CAD

Valuation Measures

Market Cap (intraday) 59.45M
Enterprise Value 38.49M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)2,085.37
Price/Book (mrq)2.30
Enterprise Value/Revenue 31,874.48
Enterprise Value/EBITDA 7-4.23

Trading Information

Stock Price History

Beta (5Y Monthly) 2.65
52-Week Change 3-62.50%
S&P500 52-Week Change 333.63%
52 Week High 30.4400
52 Week Low 30.0700
50-Day Moving Average 30.0979
200-Day Moving Average 30.1759

Share Statistics

Avg Vol (3 month) 3232.73k
Avg Vol (10 day) 3171.59k
Shares Outstanding 5111.14M
Implied Shares Outstanding 6N/A
Float 109.94M
% Held by Insiders 15.98%
% Held by Institutions 13.24%
Shares Short (May 13, 2021) 422.63k
Short Ratio (May 13, 2021) 40.15
Short % of Float (May 13, 2021) 4N/A
Short % of Shares Outstanding (May 13, 2021) 40.02%
Shares Short (prior month Apr. 14, 2021) 45.26k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2020
Most Recent Quarter (mrq)Mar. 30, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-44,405.03%

Management Effectiveness

Return on Assets (ttm)-23.47%
Return on Equity (ttm)-464.97%

Income Statement

Revenue (ttm)4.53k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)1.73k
EBITDA -2.01M
Net Income Avi to Common (ttm)-23.68M
Diluted EPS (ttm)-0.3330
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.51M
Total Cash Per Share (mrq)0.01
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)9.07
Book Value Per Share (mrq)0.04

Cash Flow Statement

Operating Cash Flow (ttm)-1.3M
Levered Free Cash Flow (ttm)-1.12M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
NOVA.CN
Nova Mentis Life Science
6 months ago
NOVA.CN
Nova Mentis Life Science
6 months ago
NOVA.CN
Nova Mentis Life Science
1 year ago
NOVA.CN
Nova Mentis Life Science
1 year ago
NOVA.CN
Nova Mentis Life Science
1 year ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago
NOVA.CN
Nova Mentis Life Science
2 years ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
5.98%% of Shares Held by All Insider
3.24%% of Shares Held by Institutions
3.44%% of Float Held by Institutions
1Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Nova Mentis Life Science Corp.


Nova Mentis to Present at the H.C. Wainwright Psychedelics Conference

Nova Mentis to Present at the H.C. Wainwright Psychedelics Conference

VANCOUVER, BC, June 10, 2021 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: LIBFF) ("NOVA"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will be presenting at the H.C. Wainwright Psy... Read More...
Nova Mentis Launches Autism Microbiome Study in the United States

Nova Mentis Launches Autism Microbiome Study in the United States

VANCOUVER, BC, March 3, 2021 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA"), a leader in the development of psilocybin and other entheogens, is pleased to announce the launch of its US-based Observational Study NM-101: "Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Diff... Read More...
Nova Mentis Autism Clinical Study Approved by Institutional Review Board

Nova Mentis Autism Clinical Study Approved by Institutional Review Board

VANCOUVER, BC, Feb. 25, 2021 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA"), a leader in the development of psilocybin and other psychedelic compounds with broad cognitive, behavioral, and peripheral physiologic effects, has received approval for its first clinical program in Autism Spectrum Disorder (ASD... Read More...
Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug

Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug

VANCOUVER, BC, Feb. 18, 2021 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that the Company is expanding its pre-clinical program to develop a novel diagnostic and treatment approach to fragile X s... Read More...
Nova Launches Preclinical Autism Spectrum Disorder Therapeutic Study

Nova Launches Preclinical Autism Spectrum Disorder Therapeutic Study

Develops Microbiome Diagnostic Index VANCOUVER, BC, Jan. 26, 2021 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that it has commenced the diagnostic and treatment phase of its ongoing preclinical model study of autism spectrum disorder (ASD). In this model, which is well accepted b... Read More...
Nova Mentis Appoints Dr. Kyle Ambert to Scientific Advisory Board

Nova Mentis Appoints Dr. Kyle Ambert to Scientific Advisory Board

VANCOUVER, BC, Jan. 4, 2021 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that it has appointed Dr. Kyle H. Ambert, PhD to its Scientific Advisory Board, effective immediately. Dr. Ambert has also agreed to become a consultant to NOVA and will assist the Company in designing precli... Read More...
Nova Mentis Uncovers Diagnostic Biomarkers in Preclinical Autism Study

Nova Mentis Uncovers Diagnostic Biomarkers in Preclinical Autism Study

VANCOUVER, BC, Dec. 8, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that it has uncovered molecular and bacteriologic diagnostic markers in its recently completed preclinical model study of autism spectrum disorder (ASD). This behavioral study, based on prenatal exposure to v... Read More...
Nova Mentis Appoints Dr. Marvin S. Hausman as Chairman of Scientific Advisory Board

Nova Mentis Appoints Dr. Marvin S. Hausman as Chairman of Scientific Advisory Board

VANCOUVER, BC, Dec. 3, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that it has appointed Dr. Marvin S. Hausman, MD as Chairman of its Scientific Advisory Board, effective immediately. Dr. Hausman is the Chief Medical Officer of Pilz Bioscience Corp., a wholly-owned subsidiar... Read More...
Nova Mentis Life Science Completes Acquisition of Pilz Bioscience

Nova Mentis Life Science Completes Acquisition of Pilz Bioscience

VANCOUVER, BC, Nov. 30, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that, further to its news releases dated November 2 and November 18, 2020, the amalgamation between Pilz Bioscience Corp. ("Pilz") and 1271642 B.C. Ltd. ("Nova Subco"), a wholly-owned subsidiary of the Compa... Read More...
Nova Mentis Life Science Announces Receipt of Pilz Shareholder Approval

Nova Mentis Life Science Announces Receipt of Pilz Shareholder Approval

VANCOUVER, BC, Nov. 18, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that, further to its news release dated November 2, 2020, the shareholders of Pilz Bioscience Corp. ("Pilz") have approved the amalgamation agreement between Pilz and 1271642 B.C. Ltd. ("Nova Subco"), a whol... Read More...
Pilz BioScience Senior Team Members To Participate In Upcoming Microdose Conference

Pilz BioScience Senior Team Members To Participate In Upcoming Microdose Conference

VANCOUVER, BC, Nov. 17, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that senior members of the Pilz Bioscience Corp. ("Pilz") team will be participating in the upcoming "The Mushroom Conference: A Molecular Masterclass" hosted by Microdose Psychedelic Insights and The Consci... Read More...
Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Provides Corporate Update

Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Provides Corporate Update

VANCOUVER, BC, Nov. 11, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. ("Pilz"), has provided a corporate update.  Dr. Marvin S. Hausman MD, Chairman and Chief Scientific Officer of Pilz commented: "We are very pleased... Read More...
Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Signs Psilocybin Manufacturing Agreement

Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Signs Psilocybin Manufacturing Agreement

VANCOUVER, BC, Nov. 5, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. ("Pilz"), has entered into a psilocybin manufacturing agreement with a U.S. based pharmaceutical company with over 800 employees. Pilz will have comp... Read More...
Nova Mentis Life Science Signs Amalgamation Agreement to Acquire 100% of Pilz BioScience Corp.

Nova Mentis Life Science Signs Amalgamation Agreement to Acquire 100% of Pilz BioScience Corp.

VANCOUVER, BC, Nov. 2, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that, further to its news release dated October 9, 2020, it has entered into a definitive amalgamation agreement, (the "Definitive Agreement") with Pilz Bioscience Corp. ("Pilz") and 1271642 B.C. Ltd. ("Nova ... Read More...
Former Senior Leader of Apotex Joins Nova Mentis Life Science Board and is Named COO

Former Senior Leader of Apotex Joins Nova Mentis Life Science Board and is Named COO

VANCOUVER, BC, Sept. 17, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce the appointment of Ms. Jacqueline McConnell to its Board of Directors and as Chief Operating Officer ("COO"). Jacqueline McConnell has over twenty years of experience working for Apotex Inc., one of Canada'... Read More...
Nova Mentis Biotech Corp Signs Psilocybin Research Agreement with France-Based Physiogenex

Nova Mentis Biotech Corp Signs Psilocybin Research Agreement with France-Based Physiogenex

VANCOUVER, BC, Aug. 31, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that its wholly-owned subsidiary, Nova Mentis Biotech Corp. ("NMBC") has signed a Master Service Agreement with leading preclinical Contract Research Organization for metabolic disorders, Physiogenex. "I am... Read More...
Nova Mentis Re-Appoints Robert W.E. Laurie as Advisory Board Chair and Psychedelics Regulatory Advisor

Nova Mentis Re-Appoints Robert W.E. Laurie as Advisory Board Chair and Psychedelics Regulatory Advisor

VANCOUVER, BC, July 8, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFD) ("NOVA") is pleased to announce  Mr. Robert W.E. Laurie has been re-appointed Advisory Board Chair and additionally appointed  Psychedelics Regulatory Advisor. Robert W.E. Laurie is an international lawyer, qualified in England and called t... Read More...
Signature by Liberty Leaf Now Approved to Support Direct Billing to Veterans Affairs Canada via Medavie Blue Cross

Signature by Liberty Leaf Now Approved to Support Direct Billing to Veterans Affairs Canada via Medavie Blue Cross

Signature's Medical Device Product Offerings Include Approved Vaporizers and Hardware, Delivered Direct to ConsumersVANCOUVER , Jan. 28, 2020 - Signature By Liberty Leaf ("Signature"), a division of Liberty Leaf Holdings Ltd. (LIB.CN) (LIBFF) (HN3P.F) (" Liberty Leaf " or the "Company"), announced today that it is now approved to direct b... Read More...
Liberty Leaf's Subsidiary Just Kush Announces Receipt of Cultivation, Processing and Medical Sales Licenses from Health Canada and Provides Corporate Update

Liberty Leaf’s Subsidiary Just Kush Announces Receipt of Cultivation, Processing and Medical Sales Licenses from Health Canada and Provides Corporate Update

VANCOUVER, Dec. 16, 2019 - Liberty Leaf Holdings Inc. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) ("Liberty Leaf" or the "Company") announces that its subsidiary, Just Kush Enterprises Ltd. ("Just Kush"), has been issued standard cultivation, standard processing and sale for medical purposes licences from Health Canada under the Cannabis Regula... Read More...
Liberty Leaf Signs Definitive Contract with Cannvas to be its Exclusive Cannabis Education Provider

Liberty Leaf Signs Definitive Contract with Cannvas to be its Exclusive Cannabis Education Provider

Customized Educational Content Powered by Physician-Backed Cannvas.Me Platform VANCOUVER, May 28, 2019 - Liberty Leaf Holdings Ltd. (CSE: LIB) (OTC: LIBFF) (FSE: HN3P) ("Liberty Leaf") is pleased to announce it has signed an agreement with Cannvas MedTech Inc. ("Cannvas") (CSE: MTEC) (Frankfurt: 3CM) (OTCPK: CANVF), a leading di... Read More...
Liberty Leaf's Signature Cannabis Retail Launches Accessories Website

Liberty Leaf’s Signature Cannabis Retail Launches Accessories Website

VANCOUVER, April 8, 2019 - Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P)¬†("Liberty Leaf" or the "Company") is pleased to announce the launch of Signature Cannabis Retail's e-commerce website, an online shopping experience offering quality cannabis accessories to consumers. On the Signature site ‚Äď https://signaturebylibe... Read More...
Milestone Moment: Liberty Leaf's Subsidiary Just Kush Receives Confirmation of Readiness Notice from the Cannabis Licensing Division of Health Canada

Milestone Moment: Liberty Leaf’s Subsidiary Just Kush Receives Confirmation of Readiness Notice from the Cannabis Licensing Division of Health Canada

VANCOUVER , April 1, 2019 - Liberty Leaf Holdings Ltd. (LIB.CN) (LIBFF) (HN3P.F) (" Liberty Leaf " or the "Company") is pleased to announce that its subsidiary, Just Kush Enterprises Ltd. ("Just Kush"), has received from the Cannabis Licensing Division of Health Canada, its Confirmation of Readiness Notice ("COR Notice") in regards to its... Read More...
Liberty Leaf's Subsidiary Just Kush Receives Confirmation of Readiness Notice from the Cannabis Licensing Division of Health Canada

Liberty Leaf’s Subsidiary Just Kush Receives Confirmation of Readiness Notice from the Cannabis Licensing Division of Health Canada

VANCOUVER, April 1, 2019 - Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) ("Liberty Leaf" or the "Company") is pleased to announce that its subsidiary, Just Kush Enterprises Ltd. ("Just Kush"), has received from the Cannabis Licensing Division of Health Canada, its Confirmation of Readiness Notice ("COR Notice") in regar... Read More...
Liberty Leaf Announces Affirmation of Readiness Submission to Health Canada by Just Kush

Liberty Leaf Announces Affirmation of Readiness Submission to Health Canada by Just Kush

VANCOUVER, Nov. 29, 2018 - Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) ("Liberty Leaf" or the "Company") is pleased to announce that its subsidiary, Just Kush Enterprises Ltd. ("Just Kush"), submitted its Affirmation of Readiness ("AOR") evidence package to Health Canada on November 29, 2018. This submission is the fi... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
NOVA.CD
Canadian Securities Exchange - CSE Listed
Canadian Securities Exchange - CSE Listed0.09CAD-5.56%
HN3Q.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.05EUR0.00%
NMLSF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.07USD+7.35%
HN3Q.BE
Berlin Stock Exchange
Berlin Stock Exchange0.05EUR+6.98%
HN3Q.SG
Stuttgart Stock Exchange
Stuttgart Stock Exchange0.07EUR+35.78%

Delayed data (1h)
NameAgePositionAppointed
William Rascan
President, Chief Executive Officer, Director
--President, Chief Executive Officer, Director2012
Jamie Robinson
Chief Financial Officer
--Chief Financial Officer2017
Steven Feldman
Independent Director
--Independent Director2012
Doug Macdonell
Independent Director
--Independent Director2017


Share this page